RECORD // Company

Foghorn Therapeutics Inc.

Built 2026-11-21T11:36:00Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (3)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Foghorn Therapeutics Inc. · Ctgov · same registered legal name as 'Foghorn Therapeutics Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • FOGHORN THERAPEUTICS · Epa echo · exact name match to 'Foghorn Therapeutics Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • FOGHORN THERAPEUTICS · Epa echo · exact name match to 'Foghorn Therapeutics Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare

5 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001628280-26-071873

ItemValuePeriodFormFiledAccessionReport
Revenue$83,543,0003 months ended 2026-09-3010-Q2026-11-090001628280-26-0718732026-11-21 11:36 UTCReport an error
Net income (loss)$58,150,0003 months ended 2026-09-3010-Q2026-11-090001628280-26-0718732026-11-21 11:36 UTCReport an error
Cash and cash equivalents$80,302,000at 2026-09-3010-Q2026-11-090001628280-26-0718732026-11-21 11:36 UTCReport an error
Contract liabilities, current$18,874,000at 2026-09-3010-Q2026-11-090001628280-26-0718732026-11-21 11:36 UTCReport an error
Contract liabilities, noncurrent$127,398,000at 2026-09-3010-Q2026-11-090001628280-26-0718732026-11-21 11:36 UTCReport an error

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001822462
Ticker
FHTX
CUSIP
344174107
Record ID
sx:sec:0001822462

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

30 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-09SEC EDGAR company profile2026-11-21 11:36 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-09SEC EDGAR company profile2026-11-21 11:36 UTCReport an error
State of incorporationDE2026-11-09SEC EDGAR company profile2026-11-21 11:36 UTCReport an error
Fiscal year end (MMDD)12312026-11-09SEC EDGAR company profile2026-11-21 11:36 UTCReport an error
Business address500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE, MA, 021392026-11-09SEC EDGAR company profile2026-11-21 11:36 UTCReport an error
ExchangesNasdaq2026-11-09SEC EDGAR company profile2026-11-21 11:36 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$30,909,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 11:36 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-74,283,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 11:36 UTCReport an error
Total assets (at 2025-12-31)$198,103,0002025-12-3110-K, XBRL Assets2026-11-21 11:36 UTCReport an error
Stockholders' equity (at 2025-12-31)$-108,500,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 11:36 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$80,876,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 11:36 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-86,099,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 11:36 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$50,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 11:36 UTCReport an error
Operating lease liabilities (at 2025-12-31)$41,270,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 11:36 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-09)On November 9, 2026 , Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended (the…2026-11-09SEC EDGAR 8-K 0001628280-26-071871 (text as filed, excerpt)2026-11-21 11:36 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-09)The Company is furnishing as Exhibit 99.2 to this Current Report on Form 8-K a presentation, dated November 2026, which the Company intends to use in meetings with or presentations to investors. The information in this Item 7.01 (including Exhibit 99.2 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.2026-11-09SEC EDGAR 8-K 0001628280-26-071871 (text as filed, excerpt)2026-11-21 11:36 UTCReport an error
8-K Item 2.05, Costs Associated with Exit or Disposal Activities (filed 2026-10-01)On September 25, 2026, following review of clinical data from the Phase 1 trial of FHD-909, Foghorn Therapeutics Inc. (the “Company”) and Eli Lilly and Company (“Lilly”) made the decision not to advance the trial into the expansion phase. Further collaboration activities pursuant to the collaboration agreement between the Company and Lilly are not anticipated. As a result, Foghorn is prioritizing resources toward the programs in its portfolio with the greatest potential to address significant patient needs and create long-term value. On September 30, 2026, the Company’s Board of Directors approved a strategic reprioritization and workforce reduction to enable the Company to focus on its…2026-10-01SEC EDGAR 8-K 0001628280-26-064102 (text as filed, excerpt)2026-11-21 11:36 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-01)On October 1, 2026, the Company issued a press release related to the decision not to advance the clinical trial of FHD-909 into the expansion phase and the Company’s resulting strategic prioritization. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1. The information in Item 7.01 of this Form 8 K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended…2026-10-01SEC EDGAR 8-K 0001628280-26-064102 (text as filed, excerpt)2026-11-21 11:36 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-06)On August 6, 2026 , Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended (the “Securities…2026-08-06SEC EDGAR 8-K 0001628280-26-053817 (text as filed, excerpt)2026-11-21 11:36 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-08-06)The Company is furnishing as Exhibit 99.2 to this Current Report on Form 8-K a presentation, dated August 2026, which the Company intends to use in meetings with or presentations to investors. The information in this Item 7.01 (including Exhibit 99.2 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.2026-08-06SEC EDGAR 8-K 0001628280-26-053817 (text as filed, excerpt)2026-11-21 11:36 UTCReport an error
Largest institutional holder #1 (13F as filed): Flagship Pioneering, LLC$61,849,7062026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error
Largest institutional holder #2 (13F as filed): BVF INC/IL$28,508,9602026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error
Largest institutional holder #3 (13F as filed): FMR LLC$27,845,0752026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error
Largest institutional holder #4 (13F as filed): DEERFIELD MANAGEMENT COMPANY, L.P.$21,444,5112026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error
Largest institutional holder #5 (13F as filed): BlackRock, Inc.$12,818,9392026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error
Largest institutional holder #6 (13F as filed): RAYMOND JAMES FINANCIAL INC$12,151,0932026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error
Largest institutional holder #7 (13F as filed): Euclidean Capital LLC$7,679,9542026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error
Largest institutional holder #8 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$7,293,7022026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error
Largest institutional holder #9 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$4,446,0912026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error
Largest institutional holder #10 (13F as filed): Siren, L.L.C.$3,517,1142026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:36 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.